Gain Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Islam Khalid, was filed 12 Aug 2024.
Gain Therapeutics, Inc.: what insiders have been doing
Gain Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Gain Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 12 August 2024.
Our records for Gain Therapeutics, Inc. go back to 2021, with 9 purchases and 2 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Since the insiders bought
- +65.6%Entry US$0.94 · Close at T+365 US$1.55
- +65.6%Entry US$0.94 · Close at T+365 US$1.55
- +36.8%Entry US$1.20 · Close at T+365 US$1.63
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Gain Therapeutics, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$7.20.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 50,000 shares@ US$0.9988100.0% of flowCommon StockSEC:0001493152-24-031377:0Canonical exit: 7 Nov 2024 (T+90)
- 14,400 shares@ US$1.01100.0% of flowCommon StockSEC:0001493152-24-031378:0Canonical exit: 7 Nov 2024 (T+90)
- 12,000 shares@ US$1.21Common StockSEC:0001493152-24-025831:1Canonical exit: 29 Sept 2024 (T+90)
- 5,000 shares@ US$1.2310.4% of flowCommon StockSEC:0001493152-24-025831:0Canonical exit: 29 Sept 2024 (T+90)
- 30,000 shares@ US$3.859100.0% of flowCommon StockSEC:0001493152-24-012340:0Canonical exit: 26 Jun 2024 (T+90)
- 825 sharesCommon StockSEC:0001493152-24-011836:1
- 637 sharesCommon StockSEC:0001493152-24-011836:2
- 6,085 shares@ US$4.06Common StockSEC:0001493152-24-011836:3
- 18,750 sharesCommon StockSEC:0001493152-24-011836:0
- 206 shares@ US$2.46Common StockSEC:0001209191-23-059558:1
- 637 sharesCommon StockSEC:0001209191-23-059558:0
- 1,820 shares@ US$2.50100.0% of flowCommon StockSEC:0001104659-23-126020:0
- 825 sharesCommon StockSEC:0001209191-23-051502:0
- 54,900 sharesCommon StockSEC:0001209191-23-050380:0
- 2,550 sharesCommon StockSEC:0001209191-23-050379:0
- 3,300 sharesCommon StockSEC:0001209191-23-041027:0
- 2,482 shares@ US$2.5810.9% of flowCommon stockSEC:0001415889-22-005798:0Canonical exit: 23 Aug 2022 (T+90)
- 9,256 shares@ US$2.83Common StockSEC:0001415889-22-005501:1Canonical exit: 18 Aug 2022 (T+90)
- 4,000 shares@ US$2.7118.7% of flowCommon stockSEC:0001415889-22-005501:0Canonical exit: 17 Aug 2022 (T+90)
- 3,000 shares@ US$2.7050.0% of flowCommon StockSEC:0001415889-22-005317:0Canonical exit: 17 Aug 2022 (T+90)
- 4,922 shares@ US$7.86659.9% of flowCommon StockSEC:0001104659-21-107121:0
21 of 21 declarations
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (ticker: GANX) is a U.S.-based biotechnology company listed on the Nasdaq Global Market in the United States. For European investors, it fits the profile of a speculative small-cap biotech: the company is focused on drug discovery and development, not on an established commercial franchise. Gain Therapeutics was incorporated in Delaware on June 26, 2020, and completed its IPO in March 2021. Its operating headquarters are in Bethesda, Maryland, placing it in one of the most important biotech corridors in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058649/ganx-20260331x10q.htm))
The company’s strategy is built around novel small-molecule therapeutics aimed at diseases across several therapeutic areas, including central nervous system disorders, lysosomal storage disorders, metabolic disorders, and other conditions that may be addressed through protein degradation, including oncology. At present, the core asset is GT-02287, a clinical-stage candidate being developed for Parkinson’s disease with and without GBA1 mutations. Gain Therapeutics says it has assembled a substantial preclinical package supporting the program’s mechanism of action, in vivo pharmacology, and safety profile. In other words, the investment case currently depends heavily on clinical validation of this lead asset and the company’s ability to expand beyond a single main program. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058649/ganx-20260331x10q.htm))
Read moreShow less
From a competitive standpoint, Gain Therapeutics operates in a very crowded neurodegeneration and CNS innovation landscape, where differentiation is driven by scientific novelty, target validation, tolerability, and execution speed. The company does not yet generate product revenue and continues to report operating losses and negative operating cash flow. It has funded itself primarily through equity issuance and capital-markets transactions. As of March 31, 2026, it held $16.5 million in cash and cash equivalents. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058649/ganx-20260331x10q.htm))
Recent developments matter for investors. On March 26, 2026, the company reported its full-year 2025 results and provided a business update. It also continued to use its at-the-market equity program with Oppenheimer, under which it sold 184,662 shares in Q1 2026 and an additional 296,697 shares between April 1 and May 8, 2026. That funding pattern underscores the company’s ongoing reliance on external capital and the associated dilution risk. For GANX shareholders, the key catalysts remain clinical updates, additional preclinical validation, and any progress toward regulatory advancement of GT-02287. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058649/ganx-20260331x10q.htm))
